Mesothelin-targeted CAR-T cell therapy for solid tumors.

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Mesothelin (MSLN) is a tumor antigen overexpressed in various solid tumors.
• MSLN is a validated target for novel immunotherapeutic strategies.
• Chimeric antigen receptor (CAR) T cell therapy is a promising approach for cancer treatment.

Purpose of the Study:

• To review anti-MSLN CAR T cell immunotherapy approaches.
• To summarize preclinical and clinical data on anti-MSLN CAR T cells.
• To discuss future directions for improving anti-MSLN CAR T cell efficacy.

Main Methods:

• Review of existing literature on MSLN as a therapeutic target.
• Analysis of preclinical studies involving anti-MSLN CAR T cells.
• Summary of ongoing and completed clinical trials for anti-MSLN CAR T cell therapy.

Main Results:

• Initial clinical trials of anti-MSLN CAR T cells demonstrated acceptable safety profiles.
• The efficacy of current anti-MSLN CAR T cell therapies in solid tumors has been limited.
• Preclinical models show potential for various anti-MSLN CAR T cell strategies.

Conclusions:

• Anti-MSLN CAR T cell therapy is safe but requires optimization for efficacy.
• Strategies like regional delivery and enhanced modifications can improve tumor infiltration and persistence.
• Combination therapies hold potential for increasing the effectiveness of anti-MSLN CAR T cells in solid malignancies.